Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
07 mars 2024 07h30 HE
|
Mustang Bio, Inc.
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
16 oct. 2023 09h00 HE
|
Fortress Biotech, Inc.
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for...
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
15 juin 2023 08h00 HE
|
Fortress Biotech, Inc.
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk...
HOK Signals its Investment in Downtown Los Angeles with Studio Relocation to the Arts District
27 avr. 2023 11h00 HE
|
HOK
LOS ANGELES, April 27, 2023 (GLOBE NEWSWIRE) -- In a move that reflects its bold, creative and forward-thinking culture, HOK’s Los Angeles studio has chosen to relocate its award-winning Southern...
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
16 févr. 2023 08h30 HE
|
Fortress Biotech, Inc.
Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant ...
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
15 févr. 2023 08h30 HE
|
Fortress Biotech, Inc.
Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients Helocyte, Inc., a subsidiary...
The AJMC Institute for Value-Based Medicine Hosts “Closing the Access Gap: Ensuring Innovation Saves Lives” Event in Orange County, CA
01 sept. 2022 09h30 HE
|
The American Journal of Managed Care®
CRANBURY, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- The American Journal of Managed Care® (AJMC®), the leading multimedia peer-reviewed journal dedicated to issues in managed care, today announced...
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
02 juin 2021 09h35 HE
|
Lixte Biotechnology Holdings, Inc.
Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal modelsDue to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit...
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
21 déc. 2020 08h00 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
City of Hope launches AccessHope™, a wholly owned subsidiary dedicated to providing a first-of-its-kind, innovative cancer support model for employers to improve care, experience, outcomes and value
06 oct. 2020 10h00 HE
|
City of Hope
AccessHopeTM remotely connects patients to expertise from world-renowned national comprehensive cancer center, providing unparalleled decision support to patients and their treating physicians.City...